Vertex’s approach to research, defined over a decade ago to beat the dismal odds of success in biotech, remains core to its strategy, even as the industry evolves and technologies expand. While that strategy, which EVP and CSO David Altshuler calls “serial innovation,” has seen the company launch eight drugs since 2011 and jump market cap tiers on the success of its cystic fibrosis portfolio, it’s now being tested in other areas as Vertex expands to pain, renal disease, Type I diabetes, and more. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Altshuler discussed the rising interest in causal biology and the role of AI, noting that the fundamentals of picking targets and programs have not changed.View full story: https://www.biocentury.com/article/655408#biotech #biopharma #pharma #lifescience#RandD #DrugDevelopment #AI00:00 - Introduction02:12 - Causal Biology08:48 - AI in R&D, at Vertex16:35 - Academia-Industry Interface22:00 - Cell Therapy for Diabetes25:35 - Gene Therapy for DMD

Ver todos los episodios